Lewy-Body Dementia

If any of the terms on this page are unclear or you want to learn more about them click here!

Lewy body dementia, or LBD, is a progressive neurodegenerative disease that can affect thinking, movement, sleep, behavior, mood, and automatic body functions such as blood pressure and digestion. One reason LBD can be difficult to recognize is that it sits at the intersection of Alzheimer’s disease and Parkinson’s disease. A person may have memory or attention problems, Parkinson-like movement symptoms, vivid visual hallucinations, and sleep or blood pressure problems at the same time.

LBD is an umbrella term that includes two closely related diagnoses: dementia with Lewy bodies and Parkinson’s disease dementia. In dementia with Lewy bodies, cognitive symptoms begin before, at the same time as, or within about one year of parkinsonian movement symptoms. In Parkinson’s disease dementia, dementia develops after Parkinson’s movement symptoms have already been present for more than a year. This “one-year rule” is mainly a clinical convention. Biologically, the two conditions overlap substantially.

Early cognitive symptoms often involve attention, planning, problem-solving, and visual-spatial processing, such as judging distance or navigating a familiar space. Memory loss can occur, but it may be less prominent at first than it is in Alzheimer’s disease. Four especially characteristic features are fluctuations in attention or alertness, recurrent well-formed visual hallucinations, REM sleep behavior disorder, and parkinsonism such as slowed movement, stiffness, or tremor. Not every person develops every feature, and symptoms can vary considerably from one day or even one hour to the next.

Learn more about Lewy-Body Dementia.

Pathology

The defining pathology of LBD is the abnormal accumulation of a protein called alpha-synuclein. In healthy neurons, alpha-synuclein is concentrated near synapses, the junctions where neurons communicate. In LBD, the protein misfolds and collects inside neurons in structures called Lewy bodies and Lewy neurites. Similar alpha-synuclein pathology occurs in Parkinson’s disease, which helps explain why the two disorders share so many symptoms.

Lewy pathology can affect several brain systems at once. Damage to cortical networks contributes to cognitive and visual-spatial problems. Loss of dopamine-producing neurons in movement circuits produces parkinsonism, while degeneration of acetylcholine-producing systems contributes to problems with attention, cognition, and hallucinations. Brainstem and peripheral autonomic pathways can also be affected, leading to REM sleep behavior disorder, constipation, urinary problems, or a drop in blood pressure when standing.

The relationship between Lewy bodies and symptoms is not completely straightforward. Small, soluble forms of abnormal alpha-synuclein may be harmful before large Lewy bodies become visible, and the location and burden of pathology vary among patients. Many people with LBD also have amyloid-beta plaques, tau tangles, or vascular injury. These coexisting pathologies may influence which symptoms appear, how quickly the disease progresses, and how well a future treatment works.

Biological Pathways

One central pathway in LBD is protein misfolding and failed protein clearance. Abnormal alpha-synuclein can interfere with synapses, cellular membranes, and the systems neurons use to transport and recycle proteins. Misfolded alpha-synuclein can also encourage normally folded alpha-synuclein to adopt an abnormal shape, which may help pathology spread through connected neural networks.

The autophagy-lysosome system, which acts as one of the cell’s main recycling systems, is closely tied to this process. If lysosomes cannot remove damaged proteins and organelles efficiently, alpha-synuclein can accumulate. In turn, accumulating alpha-synuclein can further disrupt lysosomal function, creating a cycle in which protein stress and impaired clearance reinforce one another.

Mitochondrial dysfunction is another important pathway. Neurons require a large and steady supply of energy, and abnormal alpha-synuclein can disrupt mitochondrial membranes, energy production, and calcium balance. This increases oxidative stress and leaves vulnerable neurons less able to maintain their long axons and complex networks.

Finally, LBD is a disease of disrupted communication between brain systems. Loss of acetylcholine and dopamine changes how cognitive, visual, movement, and alertness networks function even before all of the neurons in those networks have died. Neuroinflammation may also contribute, although researchers are still working out when immune responses are protective and when they add to injury.

Causes

Most cases of LBD are sporadic, meaning there is no single identifiable cause. Age is the strongest known risk factor, and the disease most often begins after age 50. Unlike Huntington’s disease, LBD is usually not inherited in a simple, predictable pattern.

Genetics can still shape susceptibility. Variants in genes such as GBA and SNCA, which are also connected to Parkinson’s disease, can increase risk in some people. APOE, best known for its relationship to Alzheimer’s disease, also appears to influence LBD risk and the likelihood of mixed Alzheimer-type pathology. Rare families with strongly inherited Lewy body disease have been described, but they represent a small minority of cases.

Progression

LBD progresses gradually, but it often does not follow a smooth or predictable course. Some people first develop sleep problems, constipation, loss of smell, depression, or subtle visual-spatial difficulties. Others first come to medical attention because of hallucinations, cognitive fluctuations, falls, or parkinsonian movement symptoms.

As the disease advances, cognitive and movement problems usually become more pronounced. A person may have increasing difficulty with complex tasks, medication management, driving, walking, or maintaining balance. Hallucinations and delusions may become more frequent, while autonomic problems such as fainting, urinary dysfunction, and constipation can complicate daily care. Sleep disruption can affect both the patient and the caregiver.

In later stages, people often need substantial help with daily activities and may develop severe mobility, swallowing, communication, or cognitive problems. The pace varies widely between individuals. Importantly, sudden worsening over hours or days is not typical progression and may instead reflect an infection, medication effect, dehydration, pain, or delirium that needs medical evaluation.

Treatment Overview

There is currently no treatment proven to stop or reverse the underlying neurodegeneration in LBD. Treatment instead focuses on the symptoms that are most disruptive while trying not to worsen another part of the disease. This balancing act is especially important in LBD because a medication that improves movement may worsen hallucinations, while a medication used for hallucinations may worsen movement or alertness.

Cholinesterase inhibitors such as rivastigmine or donepezil are commonly used to support cognition and may also reduce hallucinations or other behavioral symptoms in some patients. Rivastigmine is specifically approved in the United States for dementia associated with Parkinson’s disease, while use in dementia with Lewy bodies depends on the clinical setting. Memantine is sometimes used, although evidence for its benefit in LBD is mixed.

Levodopa may improve stiffness and slowed movement, but the response is often less robust than in typical Parkinson’s disease and it can worsen hallucinations or confusion. It is generally introduced cautiously when movement symptoms interfere with function. Physical therapy, occupational therapy, speech and swallowing therapy, exercise, home-safety changes, and caregiver support are also central parts of treatment.

Research Direction

One major research direction is developing a reliable biological test for Lewy pathology during life. Alpha-synuclein seed amplification assays can detect the ability of misfolded alpha-synuclein to trigger further protein misfolding in samples such as cerebrospinal fluid. These tests could improve early diagnosis, distinguish biological subtypes, and make clinical trials more precise, although they still require further validation and are not yet a stand-alone answer for every patient.

A second direction is targeting alpha-synuclein itself. Researchers are studying antibodies, vaccines, small molecules, and protein-clearance strategies designed to prevent alpha-synuclein from misfolding, spreading, or accumulating. Other approaches aim to improve lysosomal recycling, stabilize mitochondria, or protect vulnerable synapses and neurons.

The field is also paying more attention to mixed pathology. A patient with Lewy bodies, amyloid, tau, and vascular injury may respond differently from someone with relatively pure alpha-synuclein disease. Better biomarkers may make it possible to identify these combinations during life and match treatment to the biology actually present in each person.

Ultimately, future therapy may need to combine symptom treatment with more than one disease-modifying strategy. LBD affects several neurotransmitter systems and cellular pathways at once, so protecting cognition, movement, sleep, and autonomic function may require a similarly broad approach.

Sources

National Institute on Aging. “Lewy Body Dementia: Causes, Symptoms, and Diagnosis.”
Ian G. McKeith et al. (2017). Diagnosis and Management of Dementia with Lewy Bodies: Fourth Consensus Report of the DLB Consortium.
Tiago Fleming Outeiro et al. (2019). Dementia with Lewy Bodies: An Update and Outlook.
John-Paul Taylor et al. (2020). New Evidence on the Management of Lewy Body Dementia.
Daniel Erskine and John-Paul Taylor. (2025). Current Strategies in the Management of Dementia with Lewy Bodies and Future Directions Based on Disease Pathophysiology.